Description
VHL Polyclonal Antibody | E-AB-66748 | Gentaur US, UK & Europe Disrtribition
Reactivity: Mouse, Rat
Host: Rabbit
Isotype: IgG
Application: WB
Research Area: Cancer, Cell Biology, Epigenetics and Nuclear Signaling, Metabolism
Background: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
Lead Time: 7~10 days
Concentration: 1 mg/mL
Storage: Store at -20°C. Avoid freeze / thaw cycles.
Immunogen: A synthetic peptide of human VHL (NP_937799.1).
Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3
Purification: Affinity purification
Dilution: WB 1:500-1:2000
Conjugation: Unconjugated
Calculated Molecular Weight: 18 kDa/19 kDa/24 kDa
Observed Molecular Weight: 24 kDa
Clonality: N/A
